{
    "clinical_study": {
        "@rank": "116071", 
        "arm_group": [
            {
                "arm_group_label": "Acute Osteomyelitis - Non MRSA", 
                "arm_group_type": "Experimental", 
                "description": "For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram)  IV (intra-venous) every 8 hours for 6 weeks."
            }, 
            {
                "arm_group_label": "Acute osteomyelitis   MRSA isolate", 
                "arm_group_type": "Experimental", 
                "description": "For treatment of Acute osteomyelitis (< 6 months duration)  MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks."
            }, 
            {
                "arm_group_label": "Prosthetic joint infection", 
                "arm_group_type": "Experimental", 
                "description": "For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy of Ceftaroline in the treatment of bone and joint\n      infections."
        }, 
        "brief_title": "Ceftaroline in the Treatment of Bone and Joint Infections", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Osteomyelitis", 
            "Joint Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteomyelitis", 
                "Arthritis, Infectious"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study evaluates the efficacy of Ceftaroline 600mg IV every 8 hours for the treatment of\n      acute osteomyelitis and/or infected joints."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults > 18 years of age with the following osteoarticular infections:\n\n               1. Infected prosthetic knee or hip (first or second episode) with 2 stage procedure\n                  planned.\n\n                  Criteria for infected joint:\n\n                    1. Sinus tract which communicates with the joint\n\n                    2. Preoperative diagnosis by diagnostic, culture positive arthrocentesis\n\n                    3. Intraoperative diagnosis-evidence of purulence/inflammation is seen\n                       by          the surgeon and/or the pathologist, and at least 2\n                       intraoperative samples grow the same organism (only 1 needed if S. aureus)\n                       OR\n\n               2. Acute osteomyelitis of an extremity Criteria for acute osteomyelitis (all 4\n                  needed)\n\n                    1. Onset less than 4 weeks prior to evaluation\n\n                    2. Radiographic (plain, MRI, TC) evidence of osteomyelitis\n\n                    3. Positive culture from bone or blood culture with organism known to cause\n                       osteomyelitis\n\n                    4. Orthopedic consultant must concur with diagnosis. PLUS: Positive bone/joint\n                       or blood culture for an organism known to  cause osteomyelitis which is\n                       Ceftaroline susceptible\n\n        Exclusion criteria:\n\n          1. Immunocompromised hosts:\n\n               1. AIDS/HIV patients\n\n               2. Cancer requiring ongoing chemotherapy or radiation therapy steroid on an ongoing\n                  basis.\n\n               3. Any condition requiring > 20 mg prednisone or equivalent\n\n               4. TNF (tumor necrosing factor) inhibitor use (ongoing)\n\n               5. Organ transplant list\n\n          2. Diabetic foot infections\n\n          3. Osteomyelitis in association with decubitus ulcers\n\n          4. Vertebral osteomyelitis/spinal epidural abscess\n\n          5. Septic bursitis\n\n          6. Gonococcal arthritis\n\n          7. Ceftaroline nonsusceptible organisms isolated from bone, joint or\n                              blood.\n\n          8. Infected external fixation devices\n\n          9. Calculated creatinine clearance < 50 mL/min at baseline\n\n         10. History of severe penicillin/B lactam allergy (ID to evaluate)\n\n         11. Intravenous drug use - lifetime exclusion\n\n         12. Patients with a nail puncture wound to foot\n\n         13. Patients at high risk for MDR (multidrug resistant) Gram negative organisms\n\n        Please note the use of antibiotic containing cement is not exclusion, as it\n                             represents standard of care in some of the infections to be studied"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005068", 
            "org_study_id": "TEF-IT-17"
        }, 
        "intervention": {
            "arm_group_label": [
                "Acute Osteomyelitis - Non MRSA", 
                "Acute osteomyelitis   MRSA isolate", 
                "Prosthetic joint infection"
            ], 
            "description": "The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.", 
            "intervention_name": "Ceftaroline", 
            "intervention_type": "Drug", 
            "other_name": [
                "Teflaro", 
                "Ceftaroline fosamil", 
                "PPI-0903", 
                "TAK-599,", 
                "ceftaroline acetate", 
                "ceftaroline prodrug", 
                "ceftaroline fosamil for injection", 
                "Ceftaroline: PPI-0903M", 
                "T 91825", 
                "Chemical Name (6R,7R)-7-{(2Z)-2-(ethoxyimino)-2-[5-", 
                "(phosphonoamino)-1,2,4-thiadiazol-3-", 
                "yl]acetamino}-3-[(4-(1-methylpyridin-1-ium-4-yl)-", 
                "1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-", 
                "azabicyclo[4.2.0]oct-2-ene-2-carboxylate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Osteoarticular infections", 
            "Osteomyelitis", 
            "Joint infections", 
            "MRSA (Methicillin- Resistant Staphylococcus Aureus)", 
            "MSSA (Methicillin- Susceptible Staphylococcus Aureus)"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "Mark.Wallace@orlandohealth.com", 
                "last_name": "Mark R. Wallace, MD", 
                "phone": "407-423-1039"
            }, 
            "contact_backup": {
                "email": "Paula.Willett@orlandohealth.com", 
                "last_name": "Paula H. Willett, RN", 
                "phone": "321.841.9623"
            }, 
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32806"
                }, 
                "name": "Orlando Regional Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Ceftaroline in the Treatment of Bone and Joint Infections", 
        "other_outcome": {
            "description": "Symptoms will be assessed daily by study team while patient is hospitalized and reviewed weekly by investigator while the patient is receiving study drug. Specific symptoms will include fever, chills, rash, nausea. diarrhea, abdominal pain, pain at the surgical/infection site, vertigo, shortness of breath, hives or other rash. A baseline physical will be performed on enrollment and repeated each week at follow up visits. Labs will checked at baseline, then daily through hospitalization and then weekly. If patient develops persistent diarrhea a stool test for C. Diff PCR (polymerase chain reaction) will be performed.", 
            "measure": "Number of participants with defined symptoms, signs and lab values as markers of safety and tolerance.", 
            "safety_issue": "Yes", 
            "time_frame": "Day one through one year after completion of study drug."
        }, 
        "overall_contact": {
            "email": "Mark.Wallace@orlandohealth.com", 
            "last_name": "Mark R Wallace, MD", 
            "phone": "407.423.1039"
        }, 
        "overall_contact_backup": {
            "email": "Mary.Bowman@orlandohealth.com", 
            "last_name": "Mary C Bowman, MD", 
            "phone": "407.423.1039"
        }, 
        "overall_official": {
            "affiliation": "Orlando Health", 
            "last_name": "Mark R. Wallace, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sustained clinical remission is defined by the absence of either clinical or microbiological evidence of failure at 1 year after study drug completion, in patients who complete the protocol's antibiotic regimen(s) and did not require subsequent antibiotics for their osteoarticular infection beyond the protocol prescribed regimen.", 
            "measure": "Sustained clinical remission from the treated osteoarticular infection", 
            "safety_issue": "No", 
            "time_frame": "1 year after study drug completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005068"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Orlando Health, Inc.", 
            "investigator_full_name": "Mark Wallace MD", 
            "investigator_title": "Infectious Disease Faculty Practice", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Initial clinical success will be measured by the agreement of the Infectious disease consultant and Orthopedic surgeon that the patient has had a positive response to therapy. Success will be measured by decrease of CRP (C reactive protein) by 50% from baseline if initially elevated, no evidence of drainage, sinus tract formation or infection related bone instability. Follow up cultures, if available are negative for originally isolated organism. In patients with prothetic joints no new warmth, tenderness or inflammation.", 
            "measure": "Initial  clinical success from the treated osteoarticular infection", 
            "safety_issue": "No", 
            "time_frame": "30 days after conclusion of study antibiotic"
        }, 
        "source": "Orlando Health, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Orlando Health, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}